American College of Clinical Pharmacy
      Search      Cart
         

ACCP Report - September 2016

Cooper-DeHoff, Haines, Kelley, Rybak, and Witt to Receive ACCP Honors


Rhonda M. Cooper-DeHoff, Stuart T. Haines, Kristi W. Kelley, Michael J. Rybak, and Daniel M. Witt have been selected by the College’s Awards Committee to receive the association’s prestigious 2016 Russell R. Miller Award, Robert M. Elenbaas Service Award, Education Award, Therapeutic Frontiers Lecture Award, and Clinical Practice Award, respectively. The awards will be presented in Hollywood, Florida, on Sunday morning, October 23, during the opening session of the College’s 2016 Annual Meeting.

Rhonda M. Cooper-DeHoff, Pharm.D., M.S., FCCP, FACC, FAHA
Dr. Cooper-DeHoff

Russell R. Miller was the founding editor of the College’s journal, Pharmacotherapy. The Russell R. Miller Award is presented in recognition of substantial contributions to the literature of clinical pharmacy, thereby advancing both clinical pharmacy practice and rational pharmacotherapy. This year’s recipient is Rhonda M. Cooper-DeHoff, Pharm.D., M.S., FCCP, FACC, FAHA, an associate professor, Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine; and associate director, Center for Pharmacogenomics, University of Florida, Gainesville, Florida. At the time of her nomination, Cooper-DeHoff had published more than 125 peer-reviewed manuscripts, with most appearing in high-impact journals. Dr. Julie Johnson, dean and distinguished professor at the University of Florida College of Pharmacy, commented on Cooper-DeHoff’s important contributions to the literature in her letter of support:

The guidelines for this award state that it can be based on a singular, high impact contribution or a sustained contribution and Dr. Cooper-DeHoff qualifies under both criteria. Her research has focused largely on hypertension, and factors that influence outcomes with antihypertensive treatment. Her singular most important contribution to the literature was a paper published in JAMA in 2010 (Cooper-DeHoff et al., JAMA 2010,304:61-8; PMID 20606150). This paper has since accrued over 500 citations…. In this paper Dr. Cooper-DeHoff describes cardiovascular outcomes in diabetic patients based on level of blood pressure control from the INVEST trial. She showed that patients with tight and usual BP control had significantly better outcomes than those with uncontrolled BP, while there were no differences in outcomes between those with tight versus usual BP control. This was a seminal paper since, at the time, the target BP for diabetics was < 130/80 mmHg and yet these data showed no benefit of tighter BP control. These findings contributed to the subsequent loosening of BP targets for diabetics, and helped inform hypertension treatment guidelines that followed. This paper alone makes Dr. Cooper-DeHoff worthy of the Russell R. Miller Award. However, her contributions to the literature in hypertension go far beyond this single paper. She has over 120 publications and many have been of high impact, helping to define demographic, clinical, metabolic, metabolomic and genetic factors associated with responses to antihypertensive drugs and cardiovascular outcomes with antihypertensive therapy…. Collectively, Dr. Cooper-DeHoff has made substantial, high impact contributions to the literature on antihypertensive drug therapy. Few in clinical pharmacy have published papers with the level of impact that goes well beyond pharmacy of those of Dr. Cooper-DeHoff.

Cooper-DeHoff serves as an editorial board member for Cardiology Today and as a reviewer for several prestigious journals, including the British Journal of Clinical Pharmacology, Circulation, JAMA, Journal of Human Hypertension, Lancet, Nature Communications, Pharmacogenetics and Genomics, Pharmacogenomics, and Pharmacotherapy. She has previously received several other prestigious honors, including the New Investigator Award from the American Heart Association, Council on Basic Cardiovascular Sciences in 2001; recognition as a fellow of the American Heart Association in 2007 and the American College of Cardiology in 2010; Top Population Science Paper Award from the American Heart Association journal Hypertension in 2011; ACCP Fellow recognition in 2014; and Distinguished Associate Award from the American College of Cardiology in 2015.

Stuart T. Haines, Pharm.D., BCPS, BCACP, BC-ADM
Dr. Haines

Robert M. Elenbaas served as ACCP’s founding executive director from 1986 through 2003. During his 17-year tenure, he exemplified the characteristics of a servant leader committed to the advancement of clinical pharmacy and ACCP. The Elenbaas Service Award is given only when a particularly noteworthy candidate is identified in recognition of outstanding contributions to the vitality of ACCP or to the advancement of its goals that are well above the usual devotion of time, energy, or material goods. This year’s recipient is Stuart T. Haines, Pharm.D., BCPS, BCACP, BC-ADM, a professor and director, Division of Pharmacy Professional Development, University of Mississippi School of Pharmacy in Jackson, Mississippi. Haines, a past president of ACCP, has been actively engaged in service to the College and the pharmacy profession throughout his career. Dr. Robert Talbert, also a past ACCP president, wrote in his letter of support:

Dr. Haines has served in nearly every capacity available for the American College of Clinical Pharmacy including service to ACCP in both official and non-official capacities as well as his outstanding representation of the organization to a number of external stakeholders. From involvement on many of its committees to serving as ACCP President, Stuart has been an active contributor at all levels of the organization, as well as for Pharmacotherapy and the ACCP Research Institute. By my count, he has served on or chaired more than 30 committees, task forces and other groups for ACCP. Additionally, he has authored numerous publications for the organization and from my review of his CV, it looks like he has delivered a presentation at every ACCP meeting since 2000. Dr. Haines has represented ACCP at the national level to other pharmacy organizations (including many leadership positions in these organizations) and to federal agencies in an outstanding manner. As a recognized expert in anticoagulation and diabetes management he has provided numerous training presentations, workshops and teaching materials for the members of ACCP. In addition to the many service contributions to ACCP, Dr. Haines has been an outstanding mentor for new and continuing members of ACCP and he has created opportunities for numerous members of ACCP to grow and develop their own outstanding careers.

Joseph DiPiro, dean and professor at the Virginia Commonwealth University School of Pharmacy, added in support of Dr. Haines’ nomination:

What is more difficult to see in the list of his committees and offices is the high level of enthusiasm that he consistently brings to all of his efforts with the College. He has had a substantive role in almost every ACCP meeting over the past 15 years. I am not certain what role that his involvement in other organizations plays in the Award decision, however, if you add all of his ACCP contributions to what he has done in other pharmacy organizations such as APhA and AACP it is really quite impressive. In each of his organizational roles I believe that he has a significant positive influence, one that is an inspiration to his colleagues and a role model for young faculty members and practitioners. Looking at the scope and longevity of his contributions it is hard to imagine a better candidate for the Elenbaas Service Award.

At the time of his nomination, Haines had published more than 125 peer-reviewed manuscripts, book chapters, or abstracts. He is an active reviewer and editorial board member, serving on the editorial or editorial advisory boards of numerous journals, including the American Journal of Health-System Pharmacy, American Journal of Pharmaceutical Education, Annals of Pharmacotherapy, Journal of the American Pharmacists Association, Diabetes Forecast, Current Medical Research and Opinion, and Pharmacotherapy. Haines is a Fellow of ACCP, the American Pharmacists Association, and the American Society of Health-System Pharmacists. In addition, he has received numerous awards, including the ACCP Education Award, the University of Maryland Teaching Excellence Award, and the Robert G. Leonard Lecture Award from the University of Texas and the Texas Society of Health-System Pharmacists. Haines has also been recognized as a distinguished practitioner and fellow of the National Academies of Practice.

Kristi W. Kelley, Pharm.D., FCCP, BCPS, BC-ADM, CDE
Dr. Kelley

The Education Award recognizes an ACCP member who has made substantial and outstanding contributions to clinical pharmacy education at either the professional or the postgraduate level. This year’s recipient is Kristi W. Kelley, Pharm.D., FCCP, BCPS, BC-ADM, CDE, an associate clinical professor in the Department of Pharmacy Practice at Auburn University Harrison School of Pharmacy; and clinical pharmacist, Continuity Clinics, Brookwood Baptist Internal Medicine Residency Training Program in Birmingham, Alabama. The ACCP Awards Committee noted Kelley’s many accomplishments as an educator in both the professional degree program and postgraduate settings. Dr. Debbie Byrd, dean and professor at the Bill Gatton College of Pharmacy at East Tennessee State University and a member of the ACCP Academy’s Teaching and Learning Program faculty, wrote in her letter of support:

Dr. Kelley consistently has demonstrated teaching excellence in both the classroom and patient care arenas. She has shared her innovations in clinical pharmacy education through numerous international and national presentations and peer-reviewed publications…. She has been central in the development of cutting edge clinical pharmacy education programs, from individual courses to curricular redesign…. The quality of Dr. Kelley’s teaching is notable; she has been recognized with several teaching and mentoring awards including Roche Preceptor of the Year, Auburn University Harrison School of Pharmacy (AUHSOP) Preceptor of Excellence, and most recently, the AUHSOP Excellence in Teaching Award. I had the opportunity to review Dr. Kelley’s teaching portfolio for this most recent award. I found the advanced pharmacy practice (APPE) learning experience described in her portfolio extends above and beyond the expectations of a typical primary care APPE. The design is not only sound and innovative, but scalable as well…. A description of this work was published last year in the ACCP Ambulatory Care Pharmacist’s Survival Guide…. She also has at least 10 more education or assessment focused publications, along with numerous national presentations. In addition to pharmacy students, Dr. Kelley routinely teaches pharmacy residents, medical residents, and other health care professionals in her clinical practice…. I find the evidence to support her nomination presented in her CV and teaching portfolio exceptional; not only for the incredible education outcomes achieved over the years, but also for the innovation and confirmation of the quality of her work through publications and awards. Dr. Kelley selflessly shares her clinical and educational expertise through presentations, and service to her institution and a larger audience through ACCP.

At the time of her nomination, Kelley had published more than 30 papers in peer-reviewed journals, written or cowritten 7 book chapters, and presented extensively at professional and scientific meetings (including ACCP meetings). She has also served as the chair of ACCP’s Education and Training PRN and as a member or chair of numerous ACCP committees. She was elected as an ACCP Fellow in 2012.

Michael J. Rybak, Pharm.D., MPH, FCCP
Dr. Rybak

The ACCP Therapeutic Frontiers Lecture Award recognizes an individual, including ACCP member and nonmember nominees, who has made outstanding contributions to pharmacotherapeutics in his or her field. Among the criteria for this award is the broad acknowledgment that the recipient is currently considered at the leading edge of research in the field. This year’s recipient is Michael J. Rybak, Pharm.D., MPH, FCCP, associate dean for research, professor of pharmacy and medicine, and director of the Anti-infective Research Laboratory at Wayne State University in Detroit, Michigan. He has distinguished himself as a nationally and internationally recognized researcher in infectious diseases pharmacotherapy. A focus of his work has been the pharmacokinetics and pharmacodynamics of antimicrobials in the treatment of gram-positive infections. Dr. Arnold Bayer, a professor of medicine in the David Geffen School of Medicine at the University of California Los Angeles (UCLA) and associate chief of adult infectious disease in the Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, wrote in his letter of support:

It is clear that Mike has been a “super-productive” investigator over the years, publishing more than 300 research papers. This is a publication record comparable to any top notch ID scientist currently in the field that I am aware of. In terms of advancing the field, Mike’s principle [sic] contribution, in my view, was the invention of the PK-PD chamber model that simulated endovascular infections (“artificial vegetations”). This new ex vivo model, for the first time, provided pharmacologists, microbiologists and ID investigators a way to look at “real time” PK-PD that mimicked human-like metrics. This model has allowed the simultaneous evaluation of many different antimicrobial agents at varying PK-PD regimens in terms of both efficacy and evolution of antimicrobial resistance. These are terribly important parameters for which Mike’s model has permitted parallel observations! Of note, the relevance of his chamber model has been confirmed by showing the close microbiologic outcomes of his model with experimental endocarditis in rodents. It should be underscored that other groups have used and modified Mike’s model to allow manipulation of the “fluid” component of the chamber by adding in “host defense cells” (e.g., platelets or PMNs) to more closely simulate the human endovascular environment…. To further endorse the high standing Mike has in the ID field, his work has been duly and continuously recognized by funding organizations for more than 20 years, including multiple pharmaceutical companies as well as the NIH…. Mike’s academic record, grant-gathering, international reputation, training of young researchers and students, and overall scientific contributions would place him in the top rung of ID investigators throughout the UCLA system. He is highly deserving of your organization’s Award.

At the time of his nomination, Rybak had published 308 peer-reviewed manuscripts, 16 book chapters, and countless scientific abstracts. He also has directed the training of 37 pharmacist, physician, or Ph.D. research fellows. Rybak is currently the editor-in-chief of the journal Infectious Diseases and Therapy and has served as an editorial board member of Critical Reviews in Microbiology since 2008. He is a reviewer for numerous prestigious journals, including the Annals of Internal Medicine, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, Clinical Pharmacokinetics, Drugs, Journal of Infectious Diseases, and Pharmacoeconomics. Rybak has served as a scientific editor for Pharmacotherapy since 1996. He has been elected as an ACCP Fellow and a fellow of the Infectious Diseases Society of America. He has received numerous national and international awards for his work, including the 2005 ACCP Russell R. Miller Award, the Wayne State University Distinguished Alumni Award, and numerous teaching awards. Rybak is also a founding member, past board member, and past president of the Society of Infectious Diseases Pharmacists. His Therapeutic Frontiers Lecture, titled “Antimicrobial Combination Therapy for Life Threatening Bacterial Infections; A Bedside to Bench Approach,” will be delivered at 10:45 a.m. on Sunday, October 23, in Hollywood.

Daniel M. Witt, Pharm.D., FCCP, BCPS
Dr.Witt

The ACCP Clinical Practice Award is given to a College member who has made substantial and outstanding contributions to clinical pharmacy practice. The criteria considered in identifying potential candidates include exceptional leadership in developing innovative clinical pharmacy services and sustained excellence in providing them. This year’s recipient is Daniel M. Witt, Pharm.D., FCCP, BCPS, a professor (clinical) and vice chair in the Department of Pharmacotherapy at the University of Utah College of Pharmacy in Salt Lake City, Utah. Witt, an accomplished primary care clinical pharmacist, has been instrumental in the development and study of innovative, comprehensive clinical pharmacy services in the ambulatory care setting at Kaiser Permanente Colorado (KPCO). The focus of much of his work has been the development of clinical pharmacy services in anticoagulation and cardiology. Drs. Karen McConnell and Nathan Clark highlighted Witt’s contributions to KPCO in their letter of nomination:

Dr. Witt joined Kaiser Permanente Colorado (KPCO) in 1993 where he established an innovative primary care clinical pharmacy practice. Working closely with primary care physicians and staff, Dr. Witt provided comprehensive pharmaceutical interventions to patients entrusted to his care. In addition, Dr. Witt was an educator and preceptor for primary care specialty residents and pharmacy students. It was during his time in primary care where Dr. Witt developed his passion for anticoagulation therapy management. Physician partners relied heavily on his services and word quickly spread to neighboring KPCO medical office buildings of the excellent anticoagulation clinical program at the KPCO Westminster facility…. The anticoagulation program continued to expand informally, but demand quickly outpaced capacity. Thus, four years after joining KPCO, Dr. Witt developed a business case to centralize anticoagulation services at KPCO. The Clinical Pharmacy Anticoagulation Service (CPAS) was born. As the supervisor, it was Dr. Witt’s responsibility to obtain funding, recruit, hire and train personnel as well as develop and maintain medication management protocols. The anticoagulation service quickly became one of the largest in North America and currently cares for over 9,000 anticoagulated patients…. Dr. Witt has played a central role in the development, funding, and leadership of many of the innovative clinical pharmacy services at KPCO. Although he has pursued other opportunities with the University of Utah, Dr. Witt’s mentoring over two decades at KPCO remains in the DNA of more than 100 clinical pharmacy specialists, dozens of resident[s] and countless students who emulate his leadership in pharmacy roles today. Dr. Witt’s creativity and determination played a central role in the development of ambulatory clinical pharmacy programs that have been recognized internationally as a model for clinical pharmacy in a modern health care organization.

Dr. Dennis Helling, executive director emeritus of pharmacy utilization and therapeutics at KPCO, founding ACCP member, and past ACCP president, added in his letter of support:

Dr. Witt has exceeded all expectations as a clinician, scholar, and leader. As you can see from his impressive curriculum vitae, [he] had such success as a clinician in Primary Care clinical pharmacy practice that the KP physicians quickly entrusted him with their most difficult patients…. Dr. Witt has been the consummate pioneer, advancing clinical pharmacy through organizational leadership in ASHP, ACCP (Research Institute Trustee), International Anticoagulation Forum (Board of Directors), and the International Society of Thrombosis and Hemostasis. In addition, his prolific practice-based research agenda has been recognized by state and national awards, including the 2001 Patient Safety Award for Ambulatory Health Care by the Colorado Coalition of Patient Safety, the 2005 ASHP Foundation Literature Award for Pharmacy Practice Research, and the 2013 ASHP Foundation Literature Award for Drug Therapy Research…. Dr. Witt has authored or co-authored over 60 publications, many of which are published in high-impact medical journals such as Blood, CHEST, Journal of Thrombosis and Haemostasis, Archives of Internal Medicine, JAMA, Internal Medicine and Pharmacotherapy. Furthermore, he further pioneered a vanguard research program for the PGY2 ambulatory care specialty residency program at Kaiser Permanente Colorado, which has had unparalleled success with publication of the more than 90% of residents’ projects in the peer-reviewed literature.

At the time of his nomination, Witt had published 15 review papers, 45 original research articles, and 10 book chapters. He serves as a peer reviewer for many journals, including the American Journal of Medicine, CHEST, JAMA, JAMA Internal Medicine, Journal of the Canadian Medical Association, Journal of Thrombosis and Thrombolysis, Pharmacogenomics, and Pharmacotherapy. He has served as a member of ACCP committees, the PSAP editorial board, and the ACCP Research Institute Board of Trustees. Witt has received numerous professional awards and honors, and he was recognized as an ACCP Fellow in 2004.